Zymeworks (ZYME) Total Non-Current Liabilities (2021 - 2026)
Zymeworks' (ZYME) quarterly Total Non-Current Liabilities came in at $314.3 million in Q1 2026, up 215.3% year-on-year from $99.7 million in Q1 2025, and up 304.32% quarter-over-quarter from $77.7 million in Q4 2025.
Zymeworks (ZYME) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends
Zymeworks has disclosed Total Non-Current Liabilities across 6 years of filings, most recently posting $314.3 million for Q1 2026.
- Total Non-Current Liabilities for Q1 2026 came in at $314.3 million, up 215.3% year-over-year; the trailing twelve-month figure through Mar 2026 was $314.3 million (up 215.3% YoY), and the FY2025 annual result was $77.7 million, down 37.0% from the prior year.
- Total Non-Current Liabilities came in at $314.3 million for Q1 2026 at Zymeworks, up from $77.7 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $314.3 million in Q1 2026 to a low of $73.1 million in Q2 2025.
- The 5-year median for Total Non-Current Liabilities is $117.6 million (2022), against an average of $126.8 million.
- Across the five-year window, Total Non-Current Liabilities tumbled 37.0% in 2025 and surged 215.3% in 2026, its largest moves.
- Zymeworks' Total Non-Current Liabilities stood at $154.1 million in 2022, then decreased by 25.79% to $114.4 million in 2023, then rose by 7.89% to $123.4 million in 2024, then sank by 37.0% to $77.7 million in 2025, then surged by 304.32% to $314.3 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $314.3 million (Q1 2026), $77.7 million (Q4 2025), and $76.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 64.76 Mn |
| 10 | Zymeworks | 1.73 Bn | 1.36 Bn | - | 314.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 314.35 Mn |
| Dec 31, 2025 | 77.75 Mn |
| Sep 30, 2025 | 76.93 Mn |
| Jun 30, 2025 | 73.05 Mn |
| Mar 31, 2025 | 99.70 Mn |
| Dec 31, 2024 | 123.40 Mn |
| Sep 30, 2024 | 119.25 Mn |
| Jun 30, 2024 | 108.24 Mn |
| Mar 31, 2024 | 114.16 Mn |
| Dec 31, 2023 | 114.37 Mn |
| Sep 30, 2023 | 131.73 Mn |
| Jun 30, 2023 | 152.08 Mn |
| Mar 31, 2023 | 125.70 Mn |
| Dec 31, 2022 | 154.13 Mn |
| Sep 30, 2022 | 117.57 Mn |
| Dec 31, 2021 | 137.29 Mn |